LONDON, Feb 21 (Reuters) - Shire said on Thursday it was happy with the performance of its biggest new drug hope, Vyvanse for attention deficit hyperactivity disorder (ADHD), and confident it will be approved this year to treat adults.
LONDON, Feb 21 (Reuters) - Shire said on Thursday it was happy with the performance of its biggest new drug hope, Vyvanse for attention deficit hyperactivity disorder (ADHD), and confident it will be approved this year to treat adults.
